74 related articles for article (PubMed ID: 22842045)
1. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
Kreutzman A; Jaatinen T; Greco D; Vakkila E; Richter J; Ekblom M; Hjorth-Hansen H; Stenke L; Melo T; Paquette R; Seggewiss-Bernhardt R; Guerci-Bresler A; Talbot A; Cayuela JM; Mahon FX; Porkka K; Lipton J; Partanen J; Rousselot P; Mustjoki S
Exp Hematol; 2012 Nov; 40(11):906-913.e1. PubMed ID: 22842045
[TBL] [Abstract][Full Text] [Related]
2. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
La Nasa G; Caocci G; Littera R; Atzeni S; Vacca A; Mulas O; Langiu M; Greco M; Orrù S; Orrù N; Floris A; Carcassi C
Exp Hematol; 2013 May; 41(5):424-31. PubMed ID: 23380384
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
5. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study.
Varbanova VP; Mihailova S; Naumova E; Mihaylova AP
Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Ali S; Sergeant R; O'Brien SG; Foroni L; Hedgley C; Gerrard G; Milojkovic D; Stringaris K; Khoder A; Alsuliman A; Gilleece M; Gabriel IH; Cooper N; Goldman JM; Apperley JF; Clark RE; Marin D; Rezvani K
Blood; 2012 Jul; 120(3):697-8. PubMed ID: 22822001
[No Abstract] [Full Text] [Related]
7. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
[No Abstract] [Full Text] [Related]
8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
9. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
[TBL] [Abstract][Full Text] [Related]
11. Allelic Polymorphisms of
Ureshino H; Shindo T; Kojima H; Kusunoki Y; Miyazaki Y; Tanaka H; Saji H; Kawaguchi A; Kimura S
Cancer Immunol Res; 2018 Jun; 6(6):745-754. PubMed ID: 29695383
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
13. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
14. Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.
Olsson-Strömberg U; Hermansson M; Lundán T; Ohm AC; Engdahl I; Höglund M; Simonsson B; Porkka K; Barbany G
Eur J Haematol; 2010 Nov; 85(5):399-404. PubMed ID: 20659155
[TBL] [Abstract][Full Text] [Related]
15. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
[TBL] [Abstract][Full Text] [Related]
16. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I
Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529
[TBL] [Abstract][Full Text] [Related]
17. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
18. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Hayette S; Chabane K; Michallet M; Michallat E; Cony-Makhoul P; Salesse S; Maguer-Satta V; Magaud JP; Nicolini FE
Leuk Res; 2011 Jan; 35(1):38-43. PubMed ID: 20673586
[TBL] [Abstract][Full Text] [Related]
20. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
